IP Library › Granted Patent US 11,331,279
Granted Patent B2
US 11,331,279 · App. 14/815,936 · Granted May 17, 2022

Stable cannabinoid formulations

Inventors: Kiran Kumar Vangara (Phoenix, AZ); Huaguang Li (Chandler, AZ); Ningxin Yan (Chandler, AZ); Hung Q. Nguyen (Chandler, AZ); Venkat R. Goskonda (Phoenix, AZ)
Assignee: RADIUS PHARMACEUTICALS, INC.
A61K31/05A61K9/0095A61K47/10A61K47/14A61K47/22A61K47/44
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,331,279
App. No.
14/815,936
Granted
May 17, 2022
Kind
B2
Abstract

The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.

Claims (12)

1. A stable liquid pharmaceutical formulation for oral administration comprising:

a substantially pure cannabidiol at a concentration of 31.09% by weight;

caprylic/capric triglyceride at a concentration of 68.385% by weight; and

an antioxidant consisting of about 0.20% by weight alpha-tocopherol,

wherein % by weight is of the formulation.

2. A method of treating epilepsy, comprising administering to a subject in need of epilepsy treatment an effective amount of the stable liquid pharmaceutical formulation of claim 1 .

3. The method of claim 2 , wherein the epilepsy is selected from Dravet Syndrome, Lennox Gastaut Syndrome, myoclonic seizures, juvenile myoclonic epilepsy, refractory epilepsy, juvenile spasms, West syndrome, infantile spasms, or refractory infantile spasms.

4. The method of claim 2 , wherein the epilepsy is Dravet Syndrome.

5. The method of claim 2 , wherein the epilepsy is Lennox Gastaut Syndrome.

6. The method of claim 2 , wherein the epilepsy comprises myoclonic seizures.

7. The method of claim 2 , wherein the epilepsy comprises infantile spasms.

8. The method of claim 2 , wherein the epilepsy is West Syndrome.

Assignments (16)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2024
From: RADIUS PHARMACEUTICALS, INC.
To: FRESH CUT DEVELOPMENT, LLC
Reel/Frame 068543/0020 →
RELEASE OF SECURITY INTEREST Recorded Jul 23, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: RADIUS HEALTH, INC.
Reel/Frame 068051/0671 →
SECURITY INTEREST Recorded Aug 16, 2022
From: RADIUS HEALTH, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 061179/0001 →
RELEASE OF SECURITY INTEREST Recorded Aug 15, 2022
From: MIDCAP FUNDING IV TRUST
To: RADIUS HEALTH, INC.; RADIUS PHARMACEUTICALS, INC.
Reel/Frame 061176/0914 →
RELEASE OF SECURITY INTEREST Recorded Aug 15, 2022
From: MIDCAP FINANCIAL TRUST
To: RADIUS HEALTH, INC.; RADIUS PHARMACEUTICALS, INC.
Reel/Frame 061176/0938 →
CHANGE OF ADDRESS Recorded Dec 22, 2021
From: RADIUS PHARMACEUTICALS, INC.
To: RADIUS PHARMACEUTICALS, INC.
Reel/Frame 058569/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2021
From: FRESH CUT DEVELOPMENT, LLC
To: RADIUS PHARMACEUTICALS, INC.
Reel/Frame 056262/0235 →
SECURITY AGREEMENT SUPPLEMENT (REVOLVING) Recorded Mar 17, 2021
From: RADIUS HEALTH, INC.; RADIUS PHARMACEUTICALS, INC.
To: MIDCAP FUNDING IV TRUST, AS AGENT
Reel/Frame 055632/0634 →
REAFFIRMATION, JOINDER & AMENDMENT TO SECURITY AGREEMENT (TERM) Recorded Mar 17, 2021
From: RADIUS HEALTH, INC.; RADIUS PHARMACEUTICALS, INC.; RADIUS HEALTH VENTURES, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 055632/0017 →
REAFFIRMATION, JOINDER & AMENDMENT TO SECURITY AGREEMENT (REVOLVING) Recorded Mar 17, 2021
From: RADIUS HEALTH, INC.; RADIUS PHARMACEUTICALS, INC.; RADIUS HEALTH VENTURES, INC.
To: MIDCAP FUNDING IV TRUST, AS AGENT
Reel/Frame 055632/0316 →
SECURITY AGREEMENT SUPPLEMENT (TERM) Recorded Mar 17, 2021
From: RADIUS HEALTH, INC.; RADIUS PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 055632/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2019
From: BENUVIA THERAPEUTICS INC.
To: FRESH CUT DEVELOPMENT, LLC
Reel/Frame 051381/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2019
From: INSYS THERAPEUTICS, INC; INSYS PHARMA, INC.; INSYS DEVELOPMENT COMPANY, INC.
To: FRESH CUT DEVELOPMENT, LLC
Reel/Frame 051151/0685 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2019
From: FRESH CUT DEVELOPMENT, LLC
To: BENUVIA THERAPEUTICS INC.
Reel/Frame 051151/0852 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2016
From: VANGARA, KIRAN KUMAR; LI, HUAGUANG; YAN, NINGXIN; NGUYEN, HUNG Q; GOSKONDA, VENKAT R.
To: INSYS DEVELOPMENT COMPANY, INC.
Reel/Frame 039865/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2016
From: INSYS PHARMA, INC.
To: INSYS DEVELOPMENT COMPANY, INC.
Reel/Frame 037652/0049 →
Cited By (6)
US 12,263,139 US 12,318,356 US 12,383,567 US 12,427,160 US 12,544,389 US 12,661,365